Hussain, Syed
University of Sheffield
4 papers on CoChatORCID 0000-0003-1552-511X
Most cited papers
- Verified
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine
PARP inhibition in cancer therapyProstate Cancer Treatment and Research
Cited by 2,185
- Verified
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet
Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers
Cited by 1,408
- Verified
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S. Y.-S., Fradet, Y., Oudard, S., Vulsteke, C., Morales Barrera, R., et al. (2021) · The Lancet Oncology
Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers
Cited by 643
- Verified
Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress)
Iyer, G., Siefker-Radtke, A., Milowsky, M., Shore, N., Gao, X., Reimers, M. A., Hahn, N., Cosman, R., Matsubara, N., Necchi, A., et al. (2023) · Cancer Research
Fibroblast Growth Factor ResearchLung Cancer Treatments and Mutations
Cited by 12
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free